Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01621-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Eugénie Bassères und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections, Anti-Infective Agents, Purine Nucleosides. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NLM NIH HHS, NIAID NIH HHS, Acurx Pharmaceuticals.
Abstract (Originalsprache)
Antimicrobial resistance is emerging in clinical strains of Clostridioides difficile . Ibezapolstat (IBZ) is a DNA polymerase IIIC inhibitor that has completed phase II clinical trials. IBZ has potent in vitro activity against wild-type, susceptible strains but its effect on C. difficile strains with reduced susceptibility to metronidazole (MTZ), vancomycin (VAN), or fidaxomicin (FDX) has not been tested. The primary objective of this study was to test the antibacterial properties of IBZ against multidrug-resistant C. difficile strains. The in vitro activity, bactericidal, and time-kill activity of IBZ versus comparators were evaluated against 100 clinical strains of which 59 had reduced susceptibility to other C. difficile antibiotics. Morphologic changes against a multidrug resistance strain were visualized by light and scanning electron microscopy. The overall IBZ MIC 50/90 values (µg/mL) for evaluated C. difficile strains were 4/8, compared with 2/4 for VAN, 0.5/1 for FDX, and 0.25/4 for MTZ. IBZ MIC 50/90 values did not differ based on non-susceptibility to antibiotic class or number of classes to which strains were non-susceptible. IBZ bactericidal activity was similar to the minimum inhibitory concentration (MIC) and maintained in wild-type and non-susceptible strains. Time-kill assays against two laboratory wild-type and two clinical non-susceptible strains demonstrated sustained IBZ activity despite reduced killing by comparator antibiotics for IBZ and VAN non-susceptible strains. Microscopy visualized increased cell lengthening and cellular damage in multidrug-resistant strains exposed to IBZ sub-MIC concentrations. This study demonstrated the potent antibacterial activity of IBZ against a large collection of C. difficile strains including multidrug-resistant strains. This study highlights the therapeutic potential of IBZ against multidrug-resistant strains of C. difficile .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.
ORCID-Profile: Kevin W Garey
Förderung
- NLM NIH HHS
- NIAID NIH HHS
- Acurx Pharmaceuticals
- NIH NLM Training Program
Zitieren
APA
Bassères, E., Eubank, T. A., Begum, K., Alam, M. J., Jo, J., Le, T. M., Lancaster, C. K., Gonzales-Luna, A. J., & Garey, K. W. (2024). Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01621-23
Vancouver
Bassères E, Eubank TA, Begum K, Alam MJ, Jo J, Le TM, et al. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01621-23
BibTeX
@article{Bassres2024,
author = {Bassères, Eugénie and Eubank, Taryn A and Begum, Khurshida and Alam, M Jahangir and Jo, Jinhee and Le, Thanh M and Lancaster, Chris K and Gonzales-Luna, Anne J and Garey, Kevin W},
title = {Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01621-23}
}
EUVIMED